Anna P. Durbin mainly focuses on Virology, Dengue virus, Dengue fever, Immunology and Dengue vaccine. As part of one scientific family, she deals mainly with the area of Virology, narrowing it down to issues related to the Immunogenicity, and often Plasmodium falciparum. In Dengue virus, she works on issues like Epitope, which are connected to Monoclonal antibody, Vero cell, Infectivity, Humoral immunity and Viral entry.
Her Dengue fever research is multidisciplinary, relying on both T cell and Serotype. Her Dengue vaccine research is multidisciplinary, incorporating elements of Viremia and Disease. Her research investigates the connection between Antigen and topics such as Antibody that intersect with issues in Viral life cycle.
Anna P. Durbin mostly deals with Virology, Dengue virus, Dengue fever, Immunology and Dengue vaccine. Anna P. Durbin studied Virology and Antibody that intersect with Immunity. Her studies in Dengue virus integrate themes in fields like Neutralizing antibody, Viremia, T cell, Epitope and Monoclonal antibody.
Her work deals with themes such as DNA vaccination, Disease, Immunodominance and Environmental health, which intersect with Dengue fever. Her Vaccination, Immunogenicity, Antigen and Plasmodium falciparum study, which is part of a larger body of work in Immunology, is frequently linked to CpG site, bridging the gap between disciplines. Her work carried out in the field of Dengue vaccine brings together such families of science as Clinical trial, Immune system and Intensive care medicine.
Her main research concerns Dengue virus, Virology, Dengue vaccine, Dengue fever and Vaccination. To a larger extent, she studies Immunology with the aim of understanding Dengue virus. Anna P. Durbin usually deals with Virology and limits it to topics linked to Immunodominance and Infectivity.
Her research integrates issues of Internal medicine, Randomized controlled trial, Seroconversion and Immunogenicity in her study of Dengue vaccine. The various areas that she examines in her Dengue fever study include Tetanus, B cell and Environmental health. Her Vaccination study incorporates themes from Virus, Neutralizing antibody, Seroprevalence and Immunity.
Anna P. Durbin focuses on Dengue vaccine, Dengue fever, Vaccination, Epitope and Dengue virus. Her Dengue vaccine research integrates issues from Clinical trial, Intention-to-treat analysis, Seroconversion and Intensive care medicine. Her Dengue fever research incorporates themes from Seroprevalence, Tetanus and Environmental health.
Her Vaccination study necessitates a more in-depth grasp of Virology. Her Epitope research also covers Antibody and Immunology studies. She regularly ties together related areas like Viral envelope in her Dengue virus studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prospects for a dengue virus vaccine.
Stephen S. Whitehead;Joseph E. Blaney;Anna P. Durbin;Brian R. Murphy.
Nature Reviews Microbiology (2007)
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu;Ruth D. Ellis;Donna Shaffer;Erica Fontes.
PLOS ONE (2008)
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Anna P. Durbin;Ruth A. Karron;Wellington Sun;David W. Vaughn.
American Journal of Tropical Medicine and Hygiene (2001)
Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Elissa M. Malkin;David J. Diemert;Julie H. McArthur;John R. Perreault.
Infection and Immunity (2005)
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.
Elissa M. Malkin;Anna P. Durbin;David J. Diemert;Jetsumon Sattabongkot.
Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever
Anna P. Durbin;Maria José Vargas;Kimberli Wanionek;Samantha N. Hammond.
Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization
Steevenson Nelson;Christiane A. Jost;Qinq Xu;Jessica Ess.
PLOS Pathogens (2008)
rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers
Anna P. Durbin;Stephen S. Whitehead;Julie McArthur;John R. Perreault.
The Journal of Infectious Diseases (2005)
A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
Anna P. Durbin;Beth D. Kirkpatrick;Kristen K. Pierce;Daniel Elwood.
The Journal of Infectious Diseases (2013)
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.
Kimberly A. Dowd;Christiane A. Jost;Anna P. Durbin;Stephen S. Whitehead.
PLOS Pathogens (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: